Aldeyra Therapeutics, Inc. (137.F)

3,6430 +0,0100 (+0,28%) Börsenschluss: 08:15PM CEST

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904
https://www.aldeyra.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 10

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Todd C. Brady M.D., Ph.D.	CEO, President & Director	777,53k	N/A	1972
Mr. Bruce Greenberg C.P.A., M.B.A.	Senior VP of Finance, Interim CFO & Treasurer	400,67k	N/A	1969
Dr. Stephen G. Machatha Ph.D.	Chief Development Officer	469,47k	N/A	1977
Mr. Kelly Mizer	Vice President of Commercial Strategy & Operations	N/A	N/A	N/A
David Burke	Head of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Corporate Governance

Aldeyra Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 8, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.